EHA Research Grants
At EHA, we want to accelerate the careers of promising researchers. Are you one?
Get your hematology research funded!The European Hematology Association promotes excellence in patient care, research, and education in hematology.
We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology. Read more about us and find out how you can benefit.
Stay updated with EHA
Would you like to receive hematology-related updates directly in your inbox? Click on the link below and let us know which specific messages you would like to read.
Get your hematology research funded
Do you have a great research idea, plan and budget? Apply for an EHA Research Grant by December 18, 2018 (23:59 CET).
24th EHA Congress
Join us next year at the 24th Congress of EHA to be held on June 13-16, 2019 in Amsterdam, The Netherlands. Online registration will open on January 1, 2019 and will remain open until the last day of the congress - Sunday, June 16, 2019.
EHA-SWG Scientific Meeting on Immunotherapy: The advent of CAR T cell therapy for hematologic malignancies
Join the topics-in-focus premiere meeting on February 14-16, 2019 in Amsterdam, The Netherlands.
Chair: H Einsele
Co-chair: M Hudecek
And the winners of EHA-CRTH 2018-2019 are...
Twenty young talents have been chosen to participate in a 9-month-long unique training and mentoring experience focused on clinical research in Europe, with a global scope. Meet the winners of the Clinical Research Training in Hematology (CRTH), course 2018-2019.
Nobel prize goes to immunotherapy researchers
Two cancer immunotherapy researchers received the 2018 Nobel Prize for Physiology or Medicine. James P. Allison of the United States and Tasuku Honjo of Japan received the prize for their discovery of cancer therapy by inhibition of negative immune regulation.
HemaSphere
HemaTopics: Dual Immunotherapy adds value in relapsed/refractory Hodgkin lymphoma. Cause for optimism that scientific progress in cancer immunotherapy will soon deliver tangible benefits to our patients.
Meetings calendar
Sep06
2018
Nurses Haemato-Oncolunches
Oct25
2018
21st IDWP-EBMT Educational Course 2018
Oct25
2018
ERIC International Meeting, New Frontiers on CLL Research
Latest news
Oct01
2018
Nobel prize goes to immunotherapy researchers
Sep24
2018
EHA European Hematology Exam 2018 Report
Sep07
2018
Major changes needed for patients to benefit from precision medicine
